Evidence map›Paper›PMID 27211902›Full record

ArticleJournal of proteome research2016

Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study.

Tianfu Wu, Huihua Ding, Jie Han, Cristina Arriens, Chungwen Wei, Weilu Han, Claudia Pedroza, Shan Jiang, Jennifer Anolik, Michelle Petri and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of proteome research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Lupus Nephritis Biomarkers: A Critical Review.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Review
  14. Genes · 2023
    Article
  15. Article
  16. Review
  17. Article
  18. Matrix Metalloproteinase-10 in Kidney Injury Repair and Disease.International journal of molecular sciences · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Tianfu WuDepartment Biomedical Engineering, University of Houston , Houston, Texas 77204, United States.
Huihua DingDepartment Biomedical Engineering, University of Houston , Houston, Texas 77204, United States.
Jie HanDivision of Nephrology/Rheumatology, UT Southwestern Medical Center at Dallas , Dallas, Texas 75390, United States.
Cristina ArriensDivision of Nephrology/Rheumatology, UT Southwestern Medical Center at Dallas , Dallas, Texas 75390, United States.
Chungwen WeiDivision of Rheumatology, Emory University , Atlanta, Georgia 30322, United States.
Weilu HanCenter for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston , Houston, Texas 77030, United States.
Claudia PedrozaCenter for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston , Houston, Texas 77030, United States.
Shan JiangDepartment Biomedical Engineering, University of Houston , Houston, Texas 77204, United States.
Jennifer AnolikDivision of Rheumatology, University of Rochester , Rochester, New York 14642, United States.
Michelle PetriDivision of Rheumatology, Johns Hopkins University Medical School , Baltimore, Mississippi 21205, United States.
Ignacio SanzDivision of Rheumatology, Emory University , Atlanta, Georgia 30322, United States.
Ramesh SaxenaDivision of Nephrology/Rheumatology, UT Southwestern Medical Center at Dallas , Dallas, Texas 75390, United States.
Chandra MohanDepartment Biomedical Engineering, University of Houston , Houston, Texas 77204, United States.
University of Houston · USEmory University · USThe University of Texas Southwestern Medical Center · USCenter for Clinical Research (United States) · USJohns Hopkins University · USSouthwestern Medical CenterThe University of Texas Health Science Center at Houston · USUniversity of Rochester · US

Funding

Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI JEREMY M. BOSS · 2014 to 2026
$76.6M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
Lupus CohortR01AR043727 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 1997 to 2015
$8.2M
RENAL CONTROL OF BODY COMPOSITION AND BLOOD PRESSURET32DK007257 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BAUM, MICHEL GERARD, MOE, ORSON W · 1986 to 2021
$5.0M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
Foreboding Lupus Nephritis in Minority WomanR01DK081872 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOHAN, CHANDRA · 2009 to 2013
$2.4M
NCATS NIH HHS UL1 TR001105NIAID NIH HHS R37 AI049660NIAID NIH HHS U19 AI110483NIAMS NIH HHS R01 AR043727NIDDK NIH HHS R01 DK081872NIDDK NIH HHS T32 DK007257
6 · The paper itself

Abstract

A discovery study was carried out where serum samples from 22 systemic lupus erythematosus (SLE) patients and matched healthy controls were hybridized to antibody-coated glass slide arrays that interrogated the level of 274 human proteins. On the basis of these screens, 48 proteins were selected for ELISA-based validation in an independent cohort of 28 SLE patients. Whereas AXL, ferritin, and sTNFRII were significantly elevated in patients with active lupus nephritis (LN) relative to SLE patients who were quiescent, other molecules such as OPN, sTNFRI, sTNFRII, IGFBP2, SIGLEC5, FAS, and MMP10 exhibited the capacity to distinguish SLE from healthy controls with ROC AUC exceeding 90%, all with p < 0.001 significance. These serum markers were next tested in a cohort of 45 LN patients, where serum was obtained at the time of renal biopsy. In these patients, sTNFRII exhibited the strongest correlation with eGFR (r = -0.50, p = 0.0014) and serum creatinine (r = 0.57, p = 0.0001), although AXL, FAS, and IGFBP2 also correlated with these clinical measures of renal function. When concurrent renal biopsies from these patients were examined, serum FAS, IGFBP2, and TNFRII showed significant positive correlations with renal pathology activity index, while sTNFRII displayed the highest correlation with concurrently scored renal pathology chronicity index (r = 0.57, p = 0.001). Finally, in a longitudinal cohort of seven SLE patients examined at ∼3 month intervals, AXL, ICAM-1, IGFBP2, SIGLEC5, sTNFRII, and VCAM-1 demonstrated the ability to track with concurrent disease flare, with significant subject to subject variation. In summary, serum proteins have the capacity to identify patients with active nephritis, flares, and renal pathology activity or chronicity changes, although larger longitudinal cohort studies are warranted.

Indexed as

AdultAntibodiesBiomarkersCase-Control Studiesfas ReceptorHumansLupus Erythematosus, SystemicLupus NephritisProteomeProteomicsReceptors, Tumor Necrosis Factor, Type IISeverity of Illness IndexAntibodiesBiomarkersfas ReceptorProteomeReceptors, Tumor Necrosis Factor, Type IITNFRSF1B protein, humanAXLbiomarkersFASIGFBP2nephritispathologyTNFRII

Identifiers

PMID27211902
PMCPMC5193538
OpenAlexW2408479396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.